Analysts’ Recent Ratings Changes for WAVE Life Sciences (WVE)

A number of research firms have changed their ratings and price targets for WAVE Life Sciences (NASDAQ: WVE):

• 8/4/2026 – WAVE Life Sciences had its price target lowered by Mizuho from $27.00 to $23.00. They now have an “outperform” rating on the stock.
• 8/3/2026 – WAVE Life Sciences was given a new $13.00 price target by UBS Group AG.
• 8/3/2026 – WAVE Life Sciences had its “buy” rating reaffirmed by HC Wainwright.
• 8/1/2026 – WAVE Life Sciences was downgraded by Wall Street Zen from “hold” to “strong sell”.
• 7/31/2026 – WAVE Life Sciences had its price target lowered by B. Riley Financial, Inc. from $31.00 to $22.00. They now have a “buy” rating on the stock.
• 7/31/2026 – WAVE Life Sciences had its price target lowered by Citigroup Inc. from $24.00 to $19.00. They now have a “buy” rating on the stock.
• 7/31/2026 – WAVE Life Sciences had its price target lowered by Wedbush from $15.00 to $12.00. They now have an “outperform” rating on the stock.
• 7/21/2026 – WAVE Life Sciences was upgraded by Zacks Research from “hold” to “strong-buy”.
• 7/17/2026 – WAVE Life Sciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/11/2026 – WAVE Life Sciences was given a new $13.00 price target by New Street Research.
• 6/11/2026 – WAVE Life Sciences had its “buy” rating reaffirmed by HC Wainwright.

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.